Recent advances in the epidemiology, pathophysiology, and management of thrombosis in cancer patients

Laboratory Medicine

Volumn 35, Issue 8, 2004, Pages 492-496

  Hicks, Lisa K ^a   Selby, Rita ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE; BLOOD CLOTTING FACTOR 7A; CYSTEINE PROTEINASE; CYTOKINE; D DIMER; DALTEPARIN; ENOXAPARIN; FIBRIN; FIBRINOPEPTIDE A; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTEIN C; PROTEIN S; PROTHROMBIN; TAMOXIFEN; THALIDOMIDE; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN;

BLEEDING; BLOOD CLOTTING; BRAIN CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CENTRAL VENOUS CATHETERIZATION; CLINICAL TRIAL; DISEASE MARKER; EPIDEMIOLOGICAL DATA; FIBRINOLYSIS; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; INCIDENCE; IONIZING RADIATION; LIVER CANCER; LONG TERM CARE; META ANALYSIS; MULTIPLE MYELOMA; OVARY CARCINOMA; PANCREAS CARCINOMA; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PRIMARY PREVENTION; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SYSTEMATIC REVIEW; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

EID: 3242796811     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/E0RH-URW8-8U47-2LQU     Document Type: Review

References (56)

1. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med. 2000;160:809-15.
2. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Medicine. 1999;78:285-291.
3. Baron JA, Gridley G, Weiderpass E, et al. Venous thromboembolism and cancer. Lancet. 1998;351:1077-1080.
4. Sorensen HT, Mellemkjaer L, Steffensen FH, et al. The risk of diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998;338:1169-1173.
5. Ogedegbe HO. An overview of hemostasis. Lab Med. 2002;33:948-953.
6. Mannucci PM. Markers of hypercoagulability in cancer patients. Haemostasis. 1997;27(Suppl 1):25-31.
7. Gouin-Thibault I, Samama MM. Laboratory diagnosis of the thrombophilic state in cancer patients. Semin Thrombo Hemost. 1999;25:167-72.
8. Beer JH, Haeberli A, Vogt A, et al. Coagulation markers predict survival in cancer patients. Thromb Haemost. 2002;88:745-749.
9. Buccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma: Clinical and prognostic significance. Cancer. 2003;97:3044-3052.
10. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin and cancer. Chest. 2003;124:58S-68S.
11. Maiolo A, Tua A, Grignani G. Hemostasis and cancer: Tumor cells induce the expression of tissue factor-like procoagulant activity on endothelial cells. Haematologica. 2002;87:624-628.
12. Versteeg HH, Peppelenbosch MP, Speck CA. Tissue factor signal transduction in angiogenesis. Carcinogenesis. 2003;24:1009-1013.
13. Gordon SG, Mielicki WP. Cancer procoagulant: A factor X activator, tumor marker and growth factor from malignant tissue. Blood Coagul Fibrinolysis. 1997;8:73-86.
14. Ogiichi T, Hirashima Y, Nakamura S, et al. Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation. J Neurooncol. 2000;46:1-9.
15. Rucinska M, Furman M, Skrzydlewski Z, et al. Activity of cancer procoagulant (CP) in serum of patients with cancer of lung, breast, oesophagus and colorectum. Acta Biochim Po. 1997;44:109-112.
16. Donati MB, Gambacorti-Passerini C, Casali B, et al. Cancer procoagulant in human tumor cells: Evidence from melanoma patients. Cancer Res. 1986;46(12 Pt 1):6471-6474.
17. Falanga A, Iacoviello L, Evangelista V, et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia adminstered all-trans-retinoic acid. Blood. 1995;86:1072-1081.
18. Donati MB, Falanga A, Consonni R, et al. Cancer procoagulant in acute nonlymphoid leukemia: Relationship of enzyme detection to disease activity. Thromb Haemost. 1990;64:11-16.
19. Rickles FR, Levine M, Edward RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev. 1992;11:237-248.
20. Kageshita T, Funasaka Y, Ichihashi M, et al. Differential expression of tissue factor and tissue factor pathway inhibitor in metastatic melanoma lesions. Pigment Cell Res. 2002;15:212-216.
21. Gerlach R, Scheuer T, Bohm M, et al. Increased levels of plasma tissue factor pathway inhibitor in patients with glioblastoma and intracerebral metastases. Neurol Res. 2003;25:335-338.
22. Nijziel MR, van Oerle R, Christella M, et al. Acquired resistance to activated protein C in breast cancer patients. Br J Haematol. 2003;120:117-122.
23. Zangari M, Saghafifar F, Anaissie E, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis. 2002;13:187-192.
24. De Lucia D, De Vita F, Orditura M, et al. Hypercoagulable state in patients with advanced gastrointestinal cancer: Evidence for an acquired resistance to activated protein C. Tumori. 1997;83:948-952.
25. Carroll VA, Binder BR. The role of the plasminogen activation system in cancer. Semin Thromb Hemost. 1999;25:183-197.
26. Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood. 1998;91:3093-3102.
27. Zacharski LR, Orstein DL, Gabazza EC, et al. Treatment of malignancy by activation of the plasminogen system. Semin Thromb Hemost. 2002;28:5-18.
28. Esmon CT. Does inflammation contribute to thrombotic events? Haemostasis. 2000;30(Suppl 2):34-40.
29. Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica. 2000;85:967-972.
30. Weiler H, Isermann BH. Thrombomodulin. J Thromb Haemost. 2003;1:1515-1524.
31. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001;119:132S-175S.
32. Kakkar AK, Williamson RC. Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost. 1999;25:239-243.
33. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991;9:286-294,
34. Clahsen PC, van de Velde CJH, Julien JP, et al. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: A European organization for research and treatment of cancer breast cancer cooperative group study. J Clin Oncol. 1994;12:1266-1271.
35. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988;318:404-407.
36. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479-484.
37. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Instb. 1998;90:1371-1388.
38. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614-1615.
39. Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: Implications for therapy. Blood. 2002;100:1168-1171.
40. Mitchell LG, Sutor AH, Andrew M. Hemostasis in childhood acute lymphoblastic leukemia: Coagulopathy induced by disease and treatment. Semin Thrombo Hemost. 1995;21:390-401.
41. Mitchell L, Hoogendoorn H, Giles AR, et al. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: Risk of thrombotic complications in L-asparginase-induced antithrombin III deficiency. Blood. 1994;83:386-391.
42. Holm T, Singnomklao T, Rutqvist LE, et al. Adjuvant preoperative radiotherapy in patients with rectal carcinoma: Adverse effects during long term follow-up of two randomized trials. Cancer. 1996;78:968-976.
43. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol. 2003;21:3665-3675.
44. Luciani A, Clement O, Halimi P, et al. Catheter-related upper extremity deep venous thrombosis in cancer patients: A prospective study based on Doppler US. Radiology. 2001;220:655-660.
45. Mitchell LG, Andrew M, Hanna K, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer. 2003;97:508-516.
46. Reichardt P, Kretzscmar A, Biakhov M, et al. A phase III double-blind, placebo-controlled study evaluating the efficacy and safety of daily low-molecular-weight heparins (dalteparin sodium, fragmin) in preventing catheter-related complications in cancer patients with central venous catheters. J Clin Oncol. 2002;21:1474 [Abstract].
47. Couban S, Goodyear M, Burnell M, et al. A randomized double-blind placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer. Blood. 2002;100:2769 [Abstract].
48. Conte GF, Aravena PC, Fardella PD, et al. Prophylaxis of venous thrombosis (VT) associated with central venous catheter (CVC) with low molecular weight heparin (LMWH) in hematologic malignancies. Blood. 2003;102:4195 [Abstract].
49. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994;343:886-889.
50. Kakkar AK, Kadziola Z, Williamson RCN et al. Low molecular weight heparin (LMWH) therapy and survival in advanced cancer. Blood. 2002;100:557 [Abstract].
51. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484-3488.
52. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study. Arch Intern Med. 2002;162:1729-1735.
53. Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-153.
54. Cosgrove RH, Zacharske LR, Racine E, et al. Improved cancer mortality with low-molecular-weight heparin treatment: A review of the evidence. Semin Thrombo Hemost. 2002;28:79-87.
55. Klerk CPW, Smorenburg SM, Otten J, et al. Malignancy and low molecular weight heparin: The MALT trial. J Thromb Hemost (Suppl). 2003;195 [Abstract].
56. Lee AYY, Julian JA, Levine MN, et al. Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) may improve survival in patients with non-metastatic malignancy and venous thromboembolism (VTE). J Thromb Hemost (Suppl). 2003;004 [Abstract].